Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Published Online: 2020-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Andrew M Wardley•Arlene Chan•Fabrice André•Francesco Ricci•Gregory L Price•John F Hilton•Kristen Catron•M Corona Gainford•Sara M Tolaney•Seock-Ah Im•Shom Goel•Sonya C Chapman•Stefania Zambelli•Stephen RD Johnston•Sung-Bae Kim•Tiffany A Troso-Sandoval•Zhengyu Yang
